Related Experiment Videos
Current treatment options in aggressive lymphoma.
1Consultant Haematologist, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK. Robert.Marcus@addenbrookes.nhs.uk
Leukemia & Lymphoma
|May 25, 2004
Summary
Improving long-term remission for aggressive non-Hodgkin's lymphoma (NHL) is crucial, as current CHOP chemotherapy offers only a 40% success rate. Novel strategies are needed, especially for elderly patients, to enhance treatment efficacy and reduce toxicity.
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
Clinical lymphoma, myeloma & leukemia·2022